Beauty Claims "Blur" Difference From Drugs As Cosmeceutical Market Grows
This article was originally published in The Tan Sheet
Analysts agree cosmeceuticals remain a promising growth vehicle despite the notable regulatory questions the products can create.
You may also be interested in...
Consumers picking products over medical procedures: Medical offices catering to client skin-care needs have seen a "flip" in revenue, with increased sales of skin-care products as well as injectables such as Botox rather than plastic surgery, according to Loretta Ciraldo, professor of dermatology at the University of Miami School of Medicine and principal of Dr. Loretta Skincare. Consumers have less discretionary income, and instead of coming in for a facelift they are opting for products to combat aging, she said Sept. 29 during an HBA Global Expo session entitled "The Future of Skincare: Finding Your Place in a Shifting Market." However, "there's a higher expectation on the part of the consumer" as they look for immediate results from products purchased at medical offices compared to products from traditional retail channels, Ciraldo noted
Increased scrutiny of anti-aging products with sunscreen ingredients entering the U.S. presages "a major enforcement initiative" against personal care product firms making noncompliant claims, according to a food and drug attorney who worked at FDA on import enforcement
FDA under the Obama administration may cast a sharper eye on cosmeceuticals than the agency has in years past, according to Georgia C. Ravitz, a food and drug law lawyer at Arent Fox